EP-1193: Axillary coverage by whole breast irradiation in 1 to 2 positive sentinel lymph nodes breast cancer patients  by De Santis, M.C. et al.
3rd ESTRO Forum 2015                                                                                                                                         S647 
 
 Dosimetric verification: Delta 4 system has been 
used for pre-treatment QA. 
 Patient positioning verification: cone beam CT 
(IGRT) diary. 
 
Results: The median age of the patients was: 53 years (32-
75). Breast-conserving surgery: 72%; Surgery of the axila was 
lymphadenectomy in 50% and sentinel node biopsy in 50%.  
Tumor size (TNM): T1: 50%, T2: 40%, T3: 5%, T4: 5%; positive 
axillary nodes were found in 50%.  Acute skin reactions (RTOG 
toxicity criteria): G0: 50%, G1: 42,5%, G2: 4,5%, G3: 0%, 
there was no G4 toxicity. There were no acute adverse 
cosmetic results (assessed in agreement with the Harvard 
criteria).  
Conclusions: The explored hypofractionated radiotherapeutic 
approach with VMAT and SIB seems to be feasible providing 
consistent clinical results with excellent short-to-medium-
term toxicity profile. 
However longer follow-up is required with a major number of 
patients to asses long-term outcomes.  
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Purpose/Objective: The possibility of providing a tumoricidal 
dose to sentinel lymph nodes (SLNs) and I axillary level areas 
by standard tangential fields, designed to cover whole breast 
parenchyma, is controversial. Aim of our analysis is to 
evaluate the dosimetric coverage of the I and II axillary levels 
by standard whole breast irradiation in 1 to 2 positive 
sentinel lymph nodes patients not submitted to axillary lymph 
nodes dissection (ALND), and to compare the lymph nodes 
areas coverage obtained with standard 3D tangential RT, 
static and volumetric intensity modulated radiotherapy 
(IMRT). 
Materials and Methods: Patients with 1 to 2 positive SLNs 
undergoing breast conserving therapy, without ALND, were 
included in the analysis. For each patient a simulation CT 
scan was acquired Axillary level I, II lymph node anatomic 
volumes were defined on the CT scan by the same radiation 
oncologist according to RTOG contouring atlas, in order to 
reduce interobserver variability. For each patient three 
treatment plans were performed: a 3D conventional 
tangential plan, a static IMRT plan and a volumetric IMRT, 
designed to encompass the entire breast parenchyma. The 
axillary level I and II volumes recieving 90% and 95%(V90, 
V95) of the whole breast prescribed dose were evaluated. 
Dose-volume histograms were compared by means of the 
Friedman test. 
Results: Ten patients were enrolled. All defined breast 
volumes received >95% of the prescribed dose with the three 
techniques. Median for the I axillary level was 26.4% (range 
4.7-61.3) for 3D plans, 8.6% (range 0.64 -19.1%) for static 
IMRT plan and 2.6% (range 0.4-4.7%) for volumetric IMRT 
plans (p<0.001). Median V95% for the II axillary level was 5.4% 
(range 0-14.6%), 1.9% (range 0 -15%), and 2.6% (range 0.4-
4.7%) for 3D, static IMRT and volumetric IMRT, respectively 
(p<0.001). Median V90% for the I axillary level was 39.7% 
(range 17.8-71.5%), 9.5% (range 1.3 -27.1%), and 6% (range 
1.3-11.4%) for 3D, static IMRT and volumetric IMRT, 
respectively (p<0.001). Median V90% for the II axillary level 
was 21.4% (range 3.1-42.1%), 3.7% (range 0 -28.9%), and 2.4% 
(range 0-19.9%) for 3D, static IMRT and volumetric IMRT, 
respectively (p<0.001). 
Conclusions: Results of our analysis show that standard 3D 
tangential whole breast irradiation in 1 to 2 positive SLNs 
patients, treated by BCT without ALND, failed to deliver a 
therapeutic dose to the I and II axillary levels I. The coverage 
is even lower using static and volumetric IMRT techniques.  
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Purpose/Objective: Radiobiological and clinical data suggest 
that higher dose per fraction with shortening overall 
treatment time in breast cancer patients may enhance 
locoregional control. This, ethics approved, prospective study 
was designed to evaluate the technical feasibility, toxicity 
and early results of simultaneous integrated boost (SIB) for 
locally advanced, breast cancer patients. 
Materials and Methods: Eighteen women (8 right; 10 left-
sided) received radiotherapy with SIB applying various dose 
levels in 30 fractions. Doses were individualized according to 
the stage of the disease. The regional lymph nodes received 
49.8-60 Gy, df 1.66-2 Gy, metastatic lymph nodes received 
66-69.9 Gy, df 2.2-2.33 Gy, breast with chest wall was 
irradiated with a dose 49,8-60 Gy, the whole breast to 60Gy, 
and the highest dose was delivered to the breast tumour 69.9 
Gy. Early toxicity and results were prospectively recorded 
using CTCAE 4.03, QLQ 30, QLQ Br23, and Lent Soma scale. 
All patients underwent planning CT or FDG PET-CT. The 
majority (13 patients) were treated with the use of Clinac 
IMRT-SIB, 5 patients were treated with Tomo-SIB. 
Results: The median age was 59 years (range 37 – 78). Median 
tumor size was 6 cm (range 1-12 cm). Almost all (13) patients 
presented with clinical stage IIIB of the disease, one patient 
with IIIA, two with IIIC. Two patients in stage IIA were not 
qualified to surgery, one was not suitable for resection due 
to medical conditions, the second did not agree for a surgery. 
All patients received chemotherapy, 11 patients FAC only, 
remaining various combinations with taxanes. Ten patients 
were treated with hormonal therapy, the majority of them (8 
patients) were treated with Tamoxifen. The mean dose to 
the ipsilateral lung was 16 Gy (range12.9 - 20.7). The 
percentage of lung receiving >5Gy was 74.4, >10Gy - 50.3, 
>20Gy - 25.6. The mean heart dose was 9.6 Gy (range5.4 - 
16.9) and V5Gy was 64.1, V10Gy - 28.9, V30Gy - 4.9. There 
